TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10417507

Group type: EXPERIMENTAL
Intervention: Saline infusion into the brachial artery at a rate of 2 ml/100 ml forearm min‐1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no saline infusion)
Number of subjects: 9
Study: 8771259

Group type: EXPERIMENTAL
Intervention: Mepitel (silicone rubber dressing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paraffin gauze (control)
Number of subjects: 0
Study: 1974401

Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7305608

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride, peak mean dose of 16 micro g/kg/day, administered for 10 to 11 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 25
Study: 30227423

Group type: EXPERIMENTAL
Intervention: H2‐O2 (6 L per min, H2:O2 = 2: 1) for 15 min
Number of subjects: 35

Group type: COMPARATOR
Intervention: O2 (3 L per min) for 15 min
Number of subjects: 35

Group type: COMPARATOR
Intervention: Air for 15 min
Number of subjects: 35
Study: 27082841

Group type: EXPERIMENTAL
Intervention: Emotional Processing Writing (EPW)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Fact Control Writing (FCW)
Number of subjects: 98
Study: 23688140

Group type: EXPERIMENTAL
Intervention: 12-session evidence-based family-school intervention
Number of subjects: 92
Study: 24611442

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 10-100 mg/day (children) or 25-200 mg/day (adolescents) for 8 months
Number of subjects: 40
Study: 22700995

Group type: EXPERIMENTAL
Intervention: Ganitumab (12 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Conatumumab (10 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Number of subjects: 125
Study: 17950944

Group type: EXPERIMENTAL
Intervention: Risk-based multifactorial fall prevention program
Number of subjects: 591

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 591
Study: 16834658

Group type: EXPERIMENTAL
Intervention: Proliferating cell nuclear antigen labeling index (PCNA LI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCNA LI of 20 or more
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCNA LI of less than 20
Number of subjects: 60
Study: 13129985

Group type: EXPERIMENTAL
Intervention: Azithromycin (600 mg/d for 3 days during week 1, then 600 mg/wk during weeks 2‐12; n = 3879)
Number of subjects: 7747

Group type: COMPARATOR
Intervention: Placebo (n = 3868)
Number of subjects: 7747

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 7747

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7747
Study: 10373219

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACE-I)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (heparin)
Number of subjects: 16
Study: 8763897

Group type: EXPERIMENTAL
Intervention: Conventional fractionation (CF) - 70 Gy in 35 fractions over 7 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vienna-CHART - 55.3 Gy in 33 fractions within 17 consecutive days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vienna-CHART + MMC - 55.3 Gy in 33 fractions within 17 consecutive days with mitomycin C on day 5
Number of subjects: 90
Study: 1983848

Group type: EXPERIMENTAL
Intervention: Endoscopic epinephrine injection
Number of subjects: 132

Group type: COMPARATOR
Intervention: Heat probe treatment
Number of subjects: 132
Study: 6836750

Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy (gestonorone caproate, 200 mg/week for 1 year)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy
Number of subjects: 62
Study: 30470892

Group type: EXPERIMENTAL
Intervention: Myofascial release treatment (MR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo manual lymphatic drainage treatment (PMLD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 24
Study: 29744966

Group type: EXPERIMENTAL
Intervention: Self-Book© art therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 26559447

Group type: COMPARATOR
Intervention: Normobaric normoxia (NN)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 3
Study: 24440325

Group type: EXPERIMENTAL
Intervention: None-to-mild target lesion calcium
Number of subjects: 6855

Group type: EXPERIMENTAL
Intervention: Moderate target lesion calcium
Number of subjects: 6855

Group type: EXPERIMENTAL
Intervention: Severe target lesion calcium
Number of subjects: 6855

Group type: EXPERIMENTAL
Intervention: Severe calcium presence
Number of subjects: 6855
Study: 22695903

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 500 mg twice daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Early term delivery
Number of subjects: 125

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 125
Study: 20577914

Group type: EXPERIMENTAL
Intervention: Medial-to-lateral laparoscopic right hemi-colectomy (Group M)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lateral-to-medial laparoscopic right hemi-colectomy (Group L)
Number of subjects: 48
Study: 17379431

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy (IFRT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT) followed by IFRT
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: No further treatment
Number of subjects: 53
Study: 15679751

Group type: EXPERIMENTAL
Intervention: Weekly telephone monitoring and counseling combined with a support group in the first 4 weeks (TEL)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Twice-weekly standard group counseling (STND)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Twice-weekly individualized relapse prevention (RP)
Number of subjects: 359
Study: 12162978

Group type: EXPERIMENTAL
Intervention: Rhys‐Davies exsanguinator alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rhys‐Davies exsanguinator supplemented by a 500 ml bag of intravenous fluid
Number of subjects: 100
Study: 9549710

Group type: EXPERIMENTAL
Intervention: Experimental group (Group 3) - coordination and balance training, 3 days per week, 10 minutes each day for 6 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham group (Group 2)
Number of subjects: 45
Study: 7892154

Group type: EXPERIMENTAL
Intervention: HIV-negative group
Number of subjects: 200

Group type: COMPARATOR
Intervention: HIV-positive group
Number of subjects: 200
Study: 2361795

Group type: EXPERIMENTAL
Intervention: High-dose prednisolone (120 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-dose prednisolone (60 mg/day)
Number of subjects: 22
Study: 24618

Group type: EXPERIMENTAL
Intervention: Valium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serax
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 30741001

Group type: EXPERIMENTAL
Intervention: Messages communicating comparative risk of e‐cigarettes and combusted cigarettes
Number of subjects: 1202
Study: 27161892

Group type: EXPERIMENTAL
Intervention: Peptide-based, high Protein, high omega‐3 fat (Vital AF®, Abbott Nutrition)
Number of subjects: 49

Group type: COMPARATOR
Intervention: High protein standard enteral formula (Osmolite®, Abbott Nutrition)
Number of subjects: 49
Study: 25732758

Group type: EXPERIMENTAL
Intervention: 5 mm pen needle
Number of subjects: 66

Group type: COMPARATOR
Intervention: 8 mm pen needle
Number of subjects: 66
Study: 23547487

Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Spinbrush GLOBRUSH)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Manual toothbrush (Oral-B Indicator 30 Compact Soft Toothbrush)
Number of subjects: 105
Study: 21454149

Group type: EXPERIMENTAL
Intervention: 10% C‐β‐D‐xylopyranoside‐2‐hydroxy‐propane (C‐xyloside) cream
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 19490299

Group type: EXPERIMENTAL
Intervention: Comprehensive discharge planning
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine discharge nursing care
Number of subjects: 50
Study: 17016596

Group type: EXPERIMENTAL
Intervention: CKLQ (Cobrotoxin, tramadol hydrochloride, ibuprofen)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Tramadol hydrochloride
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: CKLQ
Number of subjects: 230
Study: 14519830

Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea (4 cups/day)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Decaffeinated black tea (4 cups/day)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 143
Study: 10782811

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tenidap
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Early changes in MMP‐3 levels
Number of subjects: 20
Study: 8636192

Group type: EXPERIMENTAL
Intervention: Tubular bandage and crutches
Number of subjects: 45

Group type: COMPARATOR
Intervention: Plaster-of-Paris cast
Number of subjects: 45
Study: 1418362

Group type: EXPERIMENTAL
Intervention: Velnacrine 300 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Velnacrine 225 mg/day
Number of subjects: 0
Study: 6691478

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 14
Study: 31481453

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) for stage IIIC
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) for stage IIIC
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT) for stage IIIC
Number of subjects: 990
Study: 30368249

Group type: COMPARATOR
Intervention: 0.1% CHX solution (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299 (Lp299)
Number of subjects: 150
Study: 26920601

Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg subcutaneously every 2 weeks or 420 mg subcutaneously every month)
Number of subjects: 27564

Group type: COMPARATOR
Intervention: Matching placebo injections
Number of subjects: 27564

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564
Study: 25222893

Group type: EXPERIMENTAL
Intervention: Universal decolonization with mupirocin and chlorhexidine (CHG) bathing
Number of subjects: 9878

Group type: EXPERIMENTAL
Intervention: Targeted decolonization (screening, isolation, and decolonization of MRSA carriers)
Number of subjects: 9878

Group type: EXPERIMENTAL
Intervention: Screening and isolation (MRSA nares screening and isolation)
Number of subjects: 9878

Group type: COMPARATOR
Intervention: Comparison of all arms
Number of subjects: 9878
Study: 23207160

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARB) - candesartan
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Beta-blockers - metoprolol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of ARB and beta-blockers
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20708813

Group type: EXPERIMENTAL
Intervention: AST-120
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control strategy
Number of subjects: 0
Study: 17062657

Group type: EXPERIMENTAL
Intervention: Once-weekly strength training (1 day/week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Twice-weekly strength training (2 days/week)
Number of subjects: 18
Study: 15799683

Group type: EXPERIMENTAL
Intervention: Efalizumab 1.0 mg/kg, administered subcutaneously once weekly for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12419472

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 microg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11160538

Group type: EXPERIMENTAL
Intervention: High fat diet (45% energy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low fat diet (20% energy)
Number of subjects: 10
Study: 10211014

Group type: EXPERIMENTAL
Intervention: Continuous epidural administration of ropivacaine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine and patient‐controlled analgesia (PCA) with i.v. morphine
Number of subjects: 130

Group type: COMPARATOR
Intervention: PCA morphine alone
Number of subjects: 130
Study: 7948343

Group type: EXPERIMENTAL
Intervention: Cases of basal cell carcinoma (BCC)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Controls with no known history of BCC or SCC
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Cases of BCC
Number of subjects: 163
Study: 3284759

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined histamine and methacholine
Number of subjects: 15
Study: 28956679

Group type: EXPERIMENTAL
Intervention: Parent-implemented intervention delivered via distance video-teleconferencing
Number of subjects: 20
Study: 26988921

Group type: EXPERIMENTAL
Intervention: Termination of pregnancy (TOP) for chromosomal abnormality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Requests for TOPs in French Centres for Perinatal Diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TOPs for non-lethal fetal anomalies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parental refusal of TOP
Number of subjects: 0
Study: 25803245

Group type: EXPERIMENTAL
Intervention: Intra‐articular 20 ml of 0.25% bupivacaine 20 minutes before the start of the operation (preemptive: PE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intra‐articular bupivacaine at the end of the operation with the suction drain opened (DO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intra‐articular bupivacaine at the end of the operation with the drain kept closed for one hour postoperatively (DC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intra‐articular injection (control group: CG)
Number of subjects: 40
Study: 23769553

Group type: EXPERIMENTAL
Intervention: Cimicifuga foetida extract (group A, n = 32)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Estradiol valerate and progesterone capsule (group B, n = 32)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Estradiol valerate and medroxyprogesterone acetate (group C, n = 32)
Number of subjects: 96
Study: 21920203

Group type: EXPERIMENTAL
Intervention: Tibial and common fibular nerve block using percutaneous nerve stimulator with 10 mL of levobupivacaine injected at each nerve site.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Localization of tibial nerve using percutaneous stimulator.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Localization of common fibular nerve using percutaneous stimulator.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Localization of tibial nerve using nerve stimulator.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Localization of common fibular nerve using nerve stimulator.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Depth of needle insertion into tibial nerve.
Number of subjects: 28
Study: 18218084

Group type: EXPERIMENTAL
Intervention: 5-option decision aid (FOBT, sigmoidoscopy, combination of FOBT and sigmoidoscopy, colonoscopy, barium enema)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 2-option decision aid (FOBT and colonoscopy)
Number of subjects: 62
Study: 16524668

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 200
Study: 14650363

Group type: EXPERIMENTAL
Intervention: Sitostanol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sitostanol acetate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sitostanol oleate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10981219

Group type: EXPERIMENTAL
Intervention: Di-Te-Ki-Pol vaccine 'SSI'
Number of subjects: 270

Group type: COMPARATOR
Intervention: DT-IPV plus wholecell pertussis vaccine
Number of subjects: 270
Study: 8626963

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 22
Study: 1460749

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (baseline IOP before induction)
Number of subjects: 40
Study: 29222892

Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements (Peptamen)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 127
Study: 27067894

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise for 24 weeks
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Brisk walking for 24 weeks
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual physical activity control for 24 weeks
Number of subjects: 135
Study: 25098260

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Periocline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 60
Study: 22811009

Group type: EXPERIMENTAL
Intervention: Bortezomib plus Bevacizumab (1.3 mg/m² on days 1, 4, 8, and 11 of each 21-day cycle; Bevacizumab 15 mg/kg on day 1 of each cycle)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Bortezomib monotherapy (1.3 mg/m² on days 1, 4, 8, and 11 of each 21-day cycle)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Bortezomib plus Bevacizumab
Number of subjects: 102

Group type: COMPARATOR
Intervention: Bortezomib monotherapy
Number of subjects: 102
Study: 19811937

Group type: EXPERIMENTAL
Intervention: Tender point examination (more than 8 TPs)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Tender point examination (all patients included)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Tender point examination (less than 6 TPs)
Number of subjects: 326
Study: 18165579

Group type: EXPERIMENTAL
Intervention: Video‐before‐interview (Group 2)
Number of subjects: 209

Group type: COMPARATOR
Intervention: No‐video (Group 1)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Video‐after‐interview (Group 3)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Video groups (Group 2 and Group 3)
Number of subjects: 209
Study: 16539916

Group type: EXPERIMENTAL
Intervention: Salbutamol and terbutaline doses delivered via MDI with spacer (half the child's weight)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Salbutamol and terbutaline doses delivered via MDI with spacer (one-third of the child's weight)
Number of subjects: 324
Study: 12562445

Group type: EXPERIMENTAL
Intervention: Esomeprazole, 20 mg once daily
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Lansoprazole, 15 mg once daily
Number of subjects: 1391
Study: 11908405

Group type: EXPERIMENTAL
Intervention: 5.3% hydrogen peroxide tooth-bleaching gel, used twice daily for 2 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comparison between peroxide gel and placebo
Number of subjects: 66
Study: 9291759

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Propofol induction followed by inhalational anaesthesia with nitrous oxide and isoflurane
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Thiopentone induction followed by inhalational anaesthesia with nitrous oxide and isoflurane
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 112
Study: 8296377

Group type: EXPERIMENTAL
Intervention: Artemether (5 days intramuscular regimen)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 54
Study: 3520308

Group type: EXPERIMENTAL
Intervention: Flunarizine (up to 0.25 mg/kg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 27
Study: 30218837

Group type: EXPERIMENTAL
Intervention: Standard Consultation
Number of subjects: 188

Group type: COMPARATOR
Intervention: No Consultation
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Consultation Including Audio Review
Number of subjects: 188
Study: 26872109

Group type: EXPERIMENTAL
Intervention: peg‐IFN/RBV plus ezetimibe for 12 weeks followed by peg‐IFN/RBV for 12 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: peg‐IFN/RBV
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: peg‐IFN/RBV plus ezetimibe
Number of subjects: 144
Study: 23294347

Group type: EXPERIMENTAL
Intervention: Interpersonal goals activated (psychologically distant to psychologically close)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no goal activated)
Number of subjects: 0
Study: 23430885

Group type: EXPERIMENTAL
Intervention: Counting gram protein exchanges (1g=50‐mg Phenylalanine)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Counting Phe unit exchanges (1unit=15‐mg Phenylalanine)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Updated diet chart allowing foods containing less than 50mg Phe per serve to be considered 'free'
Number of subjects: 26
Study: 20098447

Group type: EXPERIMENTAL
Intervention: Treatment of gestational diabetes mellitus
Number of subjects: 0
Study: 19142004

Group type: EXPERIMENTAL
Intervention: Ziziphus jujuba extract
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37